The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

Liquid biopsy’s potential as a diagnostic in cancer is gaining recognition, and its advantages over tissue biopsy in non-small cell lung cancer (NSCLC) were featured in research recently ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

The two liquid biopsy panels compared were the Guardant360, from Guardant Health, Inc., which sequenced at least part of the coding sequences of 73 genes, and the PlasmaSELECT panel from Personal ...

What a blood test for cancer can tell you Looking at more than 17,628 samples collected from 15,191 patients using a test from liquid biopsy company Guardant Health, researchers from Guardant and ...

LONDON--(BUSINESS WIRE)--The global liquid biopsy market is expected to grow by USD 4.02 billion as per Technavio. This marks a significant market slow down compared to the 2019 growth estimates ...